The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Read here for a detailed financial analysis of Medifast stock post-pandemic, GLP-1 impact, and the company's collaboration ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug ...

In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...